| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Second Regular National Report on the Implementation of the Cartagena Protocol on Biosafety
Record information and status
Record ID
105872
Status
Published
Date of creation
2014-09-12 14:28 UTC (igf.moenv@gmail.com)
Date of publication
2014-09-12 14:28 UTC (igf.moenv@gmail.com)

Origin of report
Country
  • Pakistan
Contact officer for report
Coordinates
Dr Muhammad Khurshid Swati
Director General
Pakistan Environmental Protection Agency (Pak EPA)
Plot No. 42, Street No. 6, H-8/2
Islamabad, Islamabad
Pakistan, 44000
Phone:+92 51 9250713
Fax:+92 51 9250715
Email:khurshidswati@yahoo.com,mnasirn@yahoo.com,naeemashrafraja@yahoo.com
Consulted stakeholders
9. Organizations/stakeholders who were consulted or participated in the preparation of this report
All the members of Natioanl Biosafety Committee and Technical Advisory Committee relevant and related Organizations/ Institutes/ Universities/ Ministries/ Depatments were consulted for the review of this report.
Submission
10. Date of submission
2014-09-12
11. Time period covered by this report
Start date
2011-01-01
Time period covered by this report
End date
2011-12-31
Party to the Cartagena Protocol on Biosafety
12. Is your country a Party to the Cartagena Protocol on Biosafety (CPB)?
  • Yes
Article 2 – General provisions
15. Has your country introduced the necessary legal, administrative and other measures for the implementation of the Protocol?
  • A domestic regulatory framework is partially in place
16. Which specific instruments are in place for the implementation of your national biosafety framework?
  • One or more national biosafety regulations
  • One or more sets of biosafety guidelines
17. Has your country established a mechanism for the budgetary allocations of funds for the operation of its national biosafety framework?
  • No
18. Does your country have permanent staff to administer functions directly related to the national biosafety framework?
  • No
20. Has your country’s biosafety framework / laws / regulations / guidelines been submitted to the Biosafety Clearing-House (BCH)?
  • Yes
21. Here you may provide further details on the implementation of Article 2 in your country:
The Establishment of National Biosafety Centre Project was approved by the defunct Ministry of Environment (now renamed as Ministry of Climate Change) and National Biosafety Centre was established in Pakistan Environmental Protection Agency (Pak-EPA) in April, 2006.
In exercise of the powers conferred by section 31 of Pakistan Environmental Protection Act (PEPA) 1997, the Federal Government notified Pakistan Biosafety Rules Vide S.R.O.336(1)/2005 on 21st April, 2005. National Biosafety Guidelines were notified in October, 2005 which provides the procedure for the implementation of Pakistan Biosafety Rules, 2005. Biosafety Guidelines provides procedures for the research and development on LMOs/GMOs and their products, release of LMOs/GMOs and their products for field trials and release of LMOs/GMOs for commercial purpose.
National Biosafety Centre has been working to regulate GMOs/LMOS and their products related activities in the country. This Centre provides secretarial services to three committees' i.e., National Biosafety Committee (NBC), Technical Advisory Committee (TAC) and Institutional Biosafety Committees (IBCs) essential for the implementation of the entire regulatory framework. The Centre is entrusted for the regultory fuctions by the Government of Pakistan essential to regulate GMOs/LMOs and their products in the country. A number of TAC subcommittees had been had been assigned different tasks of monitoring and evaluation of Research and development,Field trials and commercialization of GMOs/LMOs and their products in the country. These subcommittees had been fuctioning as per the directions of TAC and submit their reports to TAC for furnishing recommendations to NBC for decision making.
Article 5 – Pharmaceuticals
22. Does your country regulate the transboundary movement, handling and use of living modified organisms (LMOs) which are pharmaceuticals?
  • No
24. Here you may provide further details on the implementation of Article 5 in your country:
As per Article 5 of CPB the GMOs/LMOs for pharmaceuticals are not specifically included in the Pakistan Biosafety Regulations of the country. The bioafety regulations of the country would also be applied to GMOs/LMos and their products if any such Pharmaceuticals are derived/ developed and/or imported from GMOs/LMOs and their products.
Article 6 – Transit and Contained use
25. Does your country regulate the transit of LMOs?
  • No
26. Does your country regulate the contained use of LMOs?
  • Yes
27. If you answered Yes to questions 25 or 26, has this information been submitted to the BCH?
  • No
28. Here you may provide further details on the implementation of Article 6 in your country:
Pakistan Biosafety Clearing House Mechanism is under development for information sharing among all the stakeholders regarding GMOs/LMOs and their products related activities in the country. The information regarding GMOs/LMOs and their products would be  submited after completion and launching of the web based Pakistan Biosafety Clearing House (Pak-BCH).
Articles 7 to 10 – Advance Informed Agreement (AIA) and intentional introduction of LMOs into the environment
29. Has your country adopted law(s) / regulations / administrative measures for the operation of the AIA procedure of the Protocol?
  • Yes
30. Has your country adopted a domestic regulatory framework consistent with the Protocol regarding the transboundary movement of LMOs for intentional introduction into the environment?
  • Yes
31. Has your country established a mechanism for taking decisions regarding first intentional transboundary movements of LMOs for intentional introduction into the environment?
  • Yes
32. If you answered Yes to question 31, does the mechanism also apply to cases of intentional introduction of LMOs into the environment that were not subject to transboundary movement?
  • Yes
33. Has your country established a mechanism for monitoring potential effects of LMOs that are released into the environment?
  • Yes
34. Does your country have the capacity to detect and identify LMOs?
  • Yes, to some extent
35. Has your country established legal requirements for exporters under its jurisdiction to notify in writing the competent national authority of the Party of import prior to the intentional transboundary movement of an LMO that falls within the scope of the AIA procedure?
  • Yes
36. Has your country established legal requirements for the accuracy of information contained in the notification?
  • Yes
37. Has your country ever received an application / notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • Yes
38. Has your country ever taken a decision on an application / notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • Yes
39. If you answered Yes to question 38, how many LMOs has your country approved to date for import for intentional introduction into the environment?
  • More than 10
40. If you answered Yes to question 38, how many LMOs, not imported, has your country approved to date for intentional introduction into the environment?
  • None
41. In the current reporting period, how many applications/notifications has your country received regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • More than 10
42. In the current reporting period, how many decisions has your country taken regarding intentional transboundary movements of LMOs for intentional introduction into the environment?
  • More than 10
43. With reference to the decisions taken on intentional transboundary movements of LMOs for intentional introduction into the environment, has your country received a notification from the Party(ies) of export or from the exporter(s) prior to the transboundary movement?
  • No
44. Did the notifications contain complete information (at a minimum the information specified in Annex I of the Cartagena Protocol on Biosafety)?
  • Not applicable
45. Has your country acknowledged receipt of the notifications to the notifier within ninety days of receipt?
  • Not applicable
46. Has your country informed the notifier(s) and the BCH of its decision(s)?
  • Not applicable
47. Has your country informed the notifier(s) and the BCH of its decision(s) in due time (within 270 days or the period specified in your communication to the notifier)?
  • Not applicable
48. What percentage of your country’s decisions fall into the following categories?
  • Approval of the import/use of the LMO(s) with conditions
100%
49. In cases where your country approved an import with conditions or prohibited an import, did it provide reasons on which its decisions were based to the notifier and the BCH?
  • In some cases only the notifier
50. Here you may provide further details on the implementation of Articles 7-10 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs for intentional introduction to the environment:
Pakistan had approved the import of Genetically Modified (GM) cotton and corn hybrids to be planted for the assessment and evaluation of environmental safety and performance in the agro-climatic conditions of the country.  The Confined Field Trials of GM corn hybrids are under way and moved towards the Large Scale Field Trials to establish the economic value of the GM corn crops and impacts on agricultural communities of the country.
Article 11 – Procedure for living modified organisms intended for direct use as food or feed, or for processing (LMOs-FFP)
51. Has your country adopted specific law(s) or regulation(s) for decision-making regarding domestic use, including placing on the market, of LMOs-FFP?
  • Yes
52. Has your country established legal requirements for the accuracy of information to be provided by the applicant?
  • Yes
53. Has your country established a mechanism to ensure that decisions regarding LMOs-FFP that may be subject to transboundary movement will be communicated to the Parties through the BCH?
  • No
54. Has your country established a mechanism for taking decisions on the import of LMOs-FFP?
  • Yes
55. Has your country declared through the BCH that in the absence of a regulatory framework its decisions prior to the first import of an LMO-FFP will be taken according to Article 11.6 of the Cartagena Protocol on Biosafety?
  • No
56. Has your country indicated its needs for financial and technical assistance and capacity building in respect of LMOs-FFP?
  • No
57. Has your country ever taken a decision on LMOs-FFP (either on import or domestic use)?
  • No
63. Here you may provide further details on the implementation of Article 11 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs-FFP:
The Pakistan Biosafety regulations and implementation mechanism are in place. But, no application in this regards has been received dring the reporting period. Therefore, no such decision had been made and submitted to the BCH.
Article 12 – Review of decision
64. Has your country established a mechanism for the review and change of a decision regarding an intentional transboundary movement of LMOs?
  • Yes
65. Has your country ever received a request for a review of a decision?
  • No
66. Has your country ever reviewed / changed a decision regarding an intentional transboundary movement of LMOs?
  • No
67. In the current reporting period, how many decisions were reviewed and/or changed regarding an intentional transboundary movement of an LMO?
  • None
71. Here you may provide further details on the implementation of Article 12 in your country:
As per Pakistan Biosafety Rules, 2005 the National Bioasfety Committee (NBC) on the recommendations of Technical Advisory Committee (TAC) can review and change its decisions for GMOs/LMOs and their products on receiving applications for the review and change of decision. No request had been made for the review and change of the decision for the intentional transboundary movement of GMOs/LMOs and their products during the reporting period.
Article 13 – Simplified procedure
72. Has your country established a system for the application of the simplified procedure regarding an intentional transboundary movement of LMOs?
  • No
73. Has your country ever applied the simplified procedure?
  • No
75. In the current reporting period, how many LMOs has your country applied the simplified procedure to?
  • None
76. Here you may provide further details on the implementation of Article 13 in your country:
The mechanism had not been devised and implemented as it is desired that all the applications will follow the normal course of approval process for the decision making.
Article 14 – Bilateral, regional and multilateral agreements and arrangements
77. Has your country entered into any bilateral, regional or multilateral agreements or arrangements?
  • No
80. Here you may provide further details on the implementation of Article 14 in your country:
Not Applicable
Article 15 – Risk assessment
81. Has your country established a mechanism for conducting risk assessments prior to taking decisions regarding LMOs?
  • Yes
82. If you answered Yes to question 81, does this mechanism include procedures for identifying experts to conduct the risk assessments?
  • Yes
83. Has your country established guidelines for how to conduct risk assessments prior to taking decisions regarding LMOs?
  • No
84. Has your country acquired the necessary domestic capacity to conduct risk assessment?
  • Yes
85. Has your country established a mechanism for training national experts to conduct risk assessments?
  • No
86. Has your country ever conducted a risk assessment of an LMO for intentional introduction into the environment?
  • Yes
87. Has your country ever conducted a risk assessment of an LMO intended for direct use as food or feed, or for processing?
  • No
88. If your country has taken decision(s) on LMOs for intentional introduction into the environment or on domestic use of LMOs-FFP, were risk assessments conducted for all decisions taken?
  • In some cases only
89. Has your country submitted summary reports of the risk assessments to the BCH?
  • No
90. In the current reporting period, if your country has taken decisions regarding LMOs, how many risk assessments were conducted in the context of these decisions?
  • More than 10
91. Has your country ever required the exporter to conduct the risk assessment(s)?
  • No
92. Has your country ever required the notifier to bear the cost of the risk assessment(s) of LMOs?
  • No
93. Here you may provide further details on the implementation of Article 15 in your country:
The Risk Assessments had only been conducted for the cases/ applications of intentional release of GMOs/LMOs and their prducts in the environment for field trials testing and evaluation. The Risk Assessments reports submitted by the applicants (developed by exporting and other countries) along with the applications of import of GMOs/LMOs and their products has been reviewed by TAC and its recommendations are considered for decision making by NBC.
Article 16 – Risk management
94. Has your country established and maintained appropriate and operational mechanisms, measures and strategies to regulate, manage and control risks identified in risk assessments for:
94.1) LMOs for intentional introduction into the environment?
  • Yes, to some extent
94.2) LMOs intended for direct use as food or feed, or for processing?
  • No
95. Has your country established and maintained appropriate measures to prevent unintentional transboundary movements of LMOs?
  • Yes, to some extent
96. Has your country taken measures to ensure that any LMO, whether imported or locally developed, undergoes an appropriate period of observation that is commensurate with its life-cycle or generation time before it is put to its intended use?
  • Yes
97. Has your country cooperated with other Parties with a view to identifying LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity?
  • No
98. Has your country cooperated with other Parties with a view to taking measures regarding the treatment of LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity?
  • No
99. Here you may provide further details on the implementation of Article 16 in your country, including any details regarding risk management strategies, also in case of lack of scientific certainty on potential adverse effects of LMOs:
The mechanisms for Risk Management after due Risk Assessment have been devised and in place. The risk management operational measures has been applied to the intentional introduction into the environmeent. No application for Food, Feed or for processing of LMOs/GMOs and their products had been received and processed.
Article 17 – Unintentional transboundary movements and emergency measures
100. Has your country made available to the BCH the relevant details setting out its point of contact for the purposes of receiving notifications under Article 17?
  • Yes
101. Has your country established a mechanism for addressing emergency measures in case of unintentional transboundary movements of LMOs that are likely to have significant adverse effect on biological diversity?
  • Yes
102. Has your country implemented emergency measures in response to information about releases that led, or may have led, to unintentional transboundary movements of LMOs?
  • No
103. In the current reporting period, how many times has your country received information concerning occurrences that led, or may have led, to unintentional transboundary movement(s) of one or more LMOs to or from territories under its jurisdiction?
  • Never
107. Here you may provide further details on the implementation of Article 17 in your country:
The contacts information for unintentional transboundary movements and emergency measures had been provided to the BCH. The mechanisms addressing emergency measures has been established in consultation of Ministry of Food Security and Research. No information has been received and these measures had been implemented during the reporting period.
Article 18 – Handling, transport, packaging and identification
108. Has your country taken measures to require that LMOs that are subject to transboundary movement are handled, packaged and transported under conditions of safety, taking into account relevant international rules and standards?
  • Yes
109. Has your country taken measures to require that documentation accompanying LMOs-FFP clearly identifies that, in cases where the identity of the LMOs is not known through means such as identity preservation systems, they may contain living modified organisms and are not intended for intentional introduction into the environment, as well as a contact point for further information?
  • No
110. Has your country taken measures to require that documentation accompanying LMOs-FFP clearly identifies that, in cases where the identity of the LMOs is known through means such as identity preservation systems, they contain living modified organisms and are not intended for intentional introduction into the environment, as well as a contact point for further information?
  • Yes, to some extent
111. Has your country taken measures to require that documentation accompanying LMOs that are destined for contained use clearly identifies them as living modified organisms and specifies any requirements for the safe handling, storage, transport and use, the contact point for further information, including the name and address of the individual and institution to whom the LMO are consigned?
  • Yes
112. Has your country taken measures to require that documentation accompanying LMOs that are intended for intentional introduction into the environment of the Party of import, clearly identifies them as living modified organisms; specifies the identity and relevant traits and/or characteristics, any requirements for the safe handling, storage, transport and use, the contact point for further information and, as appropriate, the name and address of the importer and exporter; and contains a declaration that the movement is in conformity with the requirements of this Protocol applicable to the exporter?
  • Yes
113. Does your country have the capacity to enforce the requirements of identification and documentation of LMOs?
  • Yes, to some extent
114. Has your country established procedures for the sampling and detection of LMOs?
  • Yes, to some extent
115. Here you may provide further details on the implementation of Article 18 in your country:
The import of GMOs and their products is governed by Pakistan Biosafety Rules, 2005 and it had been advised to the importing party to follow all the procedures and standards for safe and secure handling/ packing of GM materials. It is required to keep the record of all the movements GMOS/LMOs and their products even with in the country and to inform NBC about all such movements, usage and storageof left over materials. The limited detection facilities had been available for detection using quick identification methods. The procedures for sampling is under development. 
Article 19 – Competent National Authorities and National Focal Points
116. Has your country designated one national focal point for the Cartagena Protocol to be responsible for liaison with the Secretariat?
  • Yes
117. Has your country designated one national focal point for the Biosafety Clearing-House to liaise with the Secretariat regarding issues of relevance to the development and implementation of the BCH?
  • Yes
118. Has your country designated one or more competent national authorities, which are responsible for performing the administrative functions required by the Cartagena Protocol on Biosafety and are authorized to act on your country’s behalf with respect to those functions?
  • Yes, one
119. In case your country designated more than one competent national authority, has your country conveyed to the Secretariat the respective responsibilities of those authorities?
  • Not applicable
120. Has your country made available the required information referred in questions 116-119 to the BCH?
  • Yes, all information
121. In case your country has designated more than one competent national authority, has your country established a mechanism for the coordination of their actions prior to taking decisions regarding LMOs?
  • Not applicable
122. Has your country established adequate institutional capacity to enable the competent national authority(ies) to perform the administrative functions required by the Cartagena Protocol on Biosafety?
  • Yes, to some extent
123. Here you may provide further details on the implementation of Article 19 in your country:
All the relevant information had been provided for the National Focal points for CPB, BCH and CNA to the secretriat and BCH.
Article 20 – Information Sharing and the Biosafety Clearing-House (BCH)
124. Please provide an overview of the status of the information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH.
124.a) Existing national legislation, regulations and guidelines for implementing the Protocol, as well as information required by Parties for the advance informed agreement procedure (Article 20, paragraph 3 (a))
  • Information available and in the BCH
124.b) National laws, regulations and guidelines applicable to the import of LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 5)
  • Information available and in the BCH
124.c) Bilateral, multilateral and regional agreements and arrangements (Articles 14, paragraph 2 and 20, paragraph 3 (b))
  • Information not available
124.d) Contact details for competent national authorities (Article 19, paragraphs 2 and 3), national focal points (Article 19, paragraphs 1 and 3), and emergency contacts (Article 17, paragraph 3 (e))
  • Information available and in the BCH
124.e) Reports submitted by the Parties on the operation of the Protocol (Article 20, paragraph 3 (e))
  • Information available but not in the BCH
124.f) Decisions by a Party on regulating the transit of specific living modified organisms (LMOs) (Article 6, paragraph 1)
  • Information not available
124.g) Occurrence of unintentional transboundary movements that are likely to have significant adverse effects on biological diversity (Article 17, paragraph 1)
  • Information not available
124.h) Illegal transboundary movements of LMOs (Article 25, paragraph 3)
  • Information not available
124.i) Final decisions regarding the importation or release of LMOs (i.e. approval or prohibition, any conditions, requests for further information, extensions granted, reasons for decision) (Articles 10, paragraph 3 and 20, paragraph 3(d))
  • Information available but not in the BCH
124.j) Information on the application of domestic regulations to specific imports of LMOs (Article 14, paragraph 4)
  • Information available but not in the BCH
124.k) Final decisions regarding the domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing (Article 11, paragraph 1)
  • Information not available
124.l) Final decisions regarding the import of LMOs intended for direct use as food or feed, or for processing that are taken under domestic regulatory frameworks (Article 11, paragraph 4) or in accordance with annex III (Article 11, paragraph 6) (requirement of Article 20, paragraph 3(d))
  • Information not available
124.m) Declarations regarding the framework to be used for LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 6)
  • Information not available
124.n) Review and change of decisions regarding intentional transboundary movements of LMOs (Article 12, paragraph 1)
  • Information not available
124.o) LMOs granted exemption status by each Party (Article 13, paragraph 1)
  • Information not available
124.p) Cases where intentional transboundary movement may take place at the same time as the movement is notified to the Party of import (Article 13, paragraph 1)
  • Information not available
124.q) Summaries of risk assessments or environmental reviews of LMOs generated by regulatory processes and relevant information regarding products thereof (Article 20, paragraph 3 (c))
  • Information available but not in the BCH
125. Has your country established a mechanism for strengthening the capacity of the BCH National Focal Point to perform its administrative functions?
  • No
126. Has your country established a mechanism for the coordination among the BCH National Focal Point, the Cartagena Protocol focal point, and the competent national authority(ies) for making information available to the BCH?
  • Yes
127. Does your country use the information available in the BCH in its decision making processes on LMOs?
  • Yes, always
128. Has your country experienced difficulties accessing or using the BCH?
  • No
129. If you answered Yes to question 128, has your country reported these problems to the BCH or the Secretariat?
  • Not applicable
130. Is the information submitted by your country to the BCH complete and up-to date?
  • No
131. Here you may provide further details on the implementation of Article 20 in your country:
The process is under way to develop a hurdle free mechanism for information sharing with the BCH. The web based Pakistan Biosafety Clearing House for information sharing is under preparation and launching stage.
Article 21 – Confidential information
132. Has your country established procedures to protect confidential information received under the Protocol?
  • Yes
133. Does your country allow the notifier to identify information that is to be treated as confidential?
  • Yes, always
134. Here you may provide further details on the implementation of Article 21 in your country:
The identified confidential information by the applicant is well protected and not shared with irrelevant indiviuals and organizations.
Article 22 – Capacity-building
135. Has your country received external support or benefited from collaborative activities with other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?
  • No
137. Has your country provided support to other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?
  • No
139. Is your country eligible to receive funding from the Global Environment Facility (GEF)?
  • Yes
140. Has your country ever initiated a process to access GEF funds for building capacity in biosafety?
  • No
142. Has your country ever received funding from the GEF for building capacity in biosafety?
  • Development of national biosafety frameworks
143. During the current reporting period, has your country undertaken activities for the development and/or strengthening of human resources and institutional capacities in biosafety?
  • Yes
144. If you answered Yes to question 143, in which of the following areas were these activities undertaken?
  • Public awareness, participation and education in biosafety
  • Mass awareness and education about biosafety system in the country
145. During the current reporting period, has your country carried out a capacity-building needs assessment?
  • No
146. Does your country still have capacity-building needs?
  • Yes
147. If you answered Yes to question 146, indicate which of the following areas still need capacity-building.
  • Institutional capacity
  • Human resources capacity development and training
  • Risk assessment and other scientific and technical expertise
  • Risk management
  • Public awareness, participation and education in biosafety
  • Information exchange and data management including participation in the Biosafety Clearing-House
  • Scientific, technical and institutional collaboration at subregional, regional and international levels
  • Technology transfer
  • Identification of LMOs, including their detection
  • Socio-economic considerations
  • Implementation of the documentation requirements under Article 18.2 of the Protocol
  • Handling of confidential information
  • Measures to address unintentional and/or illegal transboundary movements of LMOs
  • Scientific biosafety research relating to LMOs
  • Taking into account risks to human health
148. Has your country developed a capacity-building strategy or action plan?
  • No
149. Has your country submitted the details of national biosafety experts to the Roster of Experts in the BCH?
  • No
150. Here you may provide further details on the implementation of Article 22 in your country, including further details about your experience in accessing GEF funds:
Not applicable
Article 23 – Public awareness and participation
151. Has your country established a strategy or put in place legislation for promoting and facilitating public awareness, education and participation concerning the safe transfer, handling and use of LMOs?
  • Yes, to some extent
152. Has your country established a biosafety website?
  • No
153. Has your country established a mechanism to ensure public access to information on living modified organisms that may be imported?
  • Yes, to a limited extent
154. Has your country established a mechanism to consult the public in the decision-making process regarding LMOs?
  • No
155. Has your country established a mechanism to make available to the public the results of decisions taken on LMOs?
  • No
156. Has your country taken any initiative to inform its public about the means of public access to the Biosafety Clearing-House?
  • No
157. In the current reporting period, has your country promoted and facilitated public awareness, education and participation concerning the safe transfer, handling and use of LMOs?
  • Yes, to a limited extent
158. If you answered Yes to question 157, has your country cooperated with other States and international bodies?
  • No
159. In the current reporting period, how many times has your country consulted the public in the decision-making process regarding LMOs and made the results of such decisions available to the public?
  • None
160. Here you may provide further details on the implementation of Article 23 in your country:
Not applicable
Article 24 – Non-Parties
161. Has your country entered into any bilateral, regional, or multilateral agreement with non-Parties regarding transboundary movements of LMOs?
  • No
162. Has your country ever imported LMOs from a non-Party?
  • Yes
163. Has your country ever exported LMOs to a non-Party?
  • No
164. If you answered Yes to questions 162 or 163, were the transboundary movements of LMOs consistent with the objective of the Cartagena Protocol on Biosafety?
  • Yes, always
165. If you answered Yes to questions 162 or 163, was information about these transboundary movements submitted to the BCH?
  • No
166. If your country is not a Party to the Cartagena Protocol, has it contributed information to the BCH on LMOs released in, or moved into, or out of, areas within its national jurisdiction?
  • Not applicable
167. Here you may provide further details on the implementation of Article 24 in your country:
Not Applicable
Article 25 – Illegal transboundary movements
168. Has your country adopted domestic measures aimed at preventing and/or penalizing transboundary movements of LMOs carried out in contravention of its domestic measures to implement this Protocol?
  • Yes
169. Has your country established a strategy for detecting illegal transboundary movements of LMOs?
  • No
170. In the current reporting period, how many times has your country received information concerning cases of illegal transboundary movements of an LMO to or from territories under its jurisdiction?
  • Never
175. Here you may provide further details on the implementation of Article 25 in your country:
Not Applicable
Article 26 – Socio-economic considerations
176. If your country has taken a decision on import, has it ever taken into account socio-economic considerations arising from the impact of the LMO on the conservation and sustainable use of biological diversity?
  • Yes
177. Has your country cooperated with other Parties on research and information exchange on any socio-economic impacts of LMOs?
  • No
178. Here you may provide further details on the implementation of Article 26 in your country:
Not Applicable
Article 27 – Liability and Redress
179. Has your country signed the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress?
  • No
180. Has your country initiated steps towards ratification, acceptance or approval of the Nagoya-Kuala Lumpur Supplementary Protocol?
  • No
181. Here you may provide further details on any activities undertaken in your country towards the implementation of the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress:
Process for ratification of Nagoya-Kuala Lumpur will soon be initiated.
Article 33 – Monitoring and reporting
182. Has your country submitted the previous national reports (Interim and First National Reports)?
  • No
183. If your country did not submit previous reports, indicate the main challenges that hindered the submission
  • Lack of financial resources to gather the necessary information
  • Difficulty in compiling the information from various sectors
Other information
184. Please use this field to provide any other information on issues related to national implementation of the Protocol, including any obstacles or impediments encountered.
Pakistan is a developing country and under financial crunch. It needs financial resources for the effective implementation of the biosafety regulations in the country. The capacities of human resource involved in the implementation of biosafety reguations are not adequate and needs to be enhannced for the further improvement of the mechanisms and streamline procedures to address CPB reguirements and obligations.
Comments on reporting format
185. Please use this field to provide any other information on difficulties that you have encountered in filling in this report.
This format of reporting  is comprehensive.
Survey on indicators of the Strategic Plan (2014)
In decision BS-VI/15, Parties requested the Executive Secretary to conduct a dedicated survey to gather information corresponding to indicators in the Strategic Plan that could not be obtained from the second national reports or through other existing mechanisms.

The answers to the survey are displayed below.
When did your national biosafety framework become operational?
indicator 1.1.1
  • 2006
Here you may provide further details
N/A
Survey 4. How many biosafety short-term training programmes and/or academic courses are offered annually in your country?
indicator 1.2.3
  • 1 per year or more
Here you may provide further details
Capacity Building activities arranged in last years are following;  i. One day workshop, "Development of National Biosafety Roadmaps in Pakistan", Organized by KOICA, in collaboration with NBC, Pak-EPA on 1st August, 2007.   ii. One day workshop, "Training Workshop for "Heads of Institutional Biosafety Committees (IBCs)" Organized by NBC, Pak-EPA Feb 04, 2008.  iii. One day seminar on "Genetically Modified Organisms (GMOs) - Applications and Implications" Organized by NBC, Pak-EPA on May 13, 2008.  iv. One day training workshop, "Role of Biosafety Officers for the Implementation of Pakistan Biosafety Rules, 2005" Organized by NBC, Pak-EPA on June 23, 2008.  v. Invited Lecture/ Seminar Series "Biodiversity Conservation: Biosafety Perspective" Dept. of Environmental Sciences in collaboration with Dept. of Zoology/Biology, PMAS Arid Agriculture University, Rawalpindi on May 27, 2010.  vi. One day Workshop, "Environmental Safety and Stewardship of Biotech Products" organized by NBC in collaboration with M/s Pioneer Pakistan Seed Ltd. on April 4, 2011.  vii. One day seminar, "GM Cotton: Food and Feed safety Prospectives" by M/s Pioneer Pakistan Seed Ltd. and NBC on April 5, 2011.  viii. An Invited Lecture on "Status of Implementation of Biosafety Regulations in Pakistan" in the "Workshop on Implementation of Biosafety Protocols" Centre of Agriculture Biochemistry and Biotechnology, University of Agriculture, Faisalabad on May 14, 2011.  ix. One day International Workshop, "Global Status, Impact and Future Prospects of Biotech Crops" organized by NBC in collaboration with M/s Monsanto Pakistan (Pvt.) Limited, Lahore on January 10, 2012  x. An Invited Lecture titled "Genetically Modified Products and their Regulation in Pakistan" Directorate of Health, Capital Development Authority (CDA), Islamabad on September 17, 2012.  xi. An Invited Lecture titled "Biosafety Laws and their Implementation" In the 121th Extra Ordinary General Body Meeting of Farmers Associates Pakistan (FAP), Lahore on November 13, 2012.  xii. An Invited Lecture titled "Responsibilities and Functions of Institutional Biosafety Committee under Pakistan Biosafety Rules 2005" at Faculty of Biological Sciences, Quad-i-Azam University, Islamabad on March 28, 2013.  xiii. "Capacity Building and Training Presentations on Trait Purity and GM Testing for TAC members and National Biosafety Centre officers" organized by NBC in collaboration with M/s Monsanto Pakistan (Pvt.) Limited, Lahore on April 10, 2013.  xiv. "Hazardous Impacts of Pesticides in Environment and their Possible Alternatives"  organized by TheNetwork for Consumer Protection at National University of Science and Technology, Islamabad on 10th October, 2013.
Survey 5. Does your country have in place a functional national mechanism for coordinating biosafety capacity-building initiatives?
indicator 1.2.4
  • No
Here you may provide further details
N/A
Survey 6. How much additional funding (in the equivalent of US dollars) has your country mobilized in the last four years to support implementation of the Biosafety Protocol, beyond the regular national budgetary allocation?
indicator 1.2.5
  • No funds mobilized
Survey 7. Does your country have predictable and reliable funding for building capacity for the effective implementation of the Protocol?
indicator 1.2.6
  • No
Here you may provide further details
N/A
Survey 8. How many LMO-related collaborative bilateral/multilateral arrangements has your country established with other Parties/non-Parties?
indicator 1.2.8
  • 10 or more
Here you may provide further details
Pakistan has established bilateral /multilateral arangements with Korea, Philipines and USA for capacity building activities. The executed activites are listed bellow:    i. Three (03) Korean Experts in the Field of Biotechnology, Biotechnology Information System, and Legal Expert in the field of Biosafety were dispatched to NBC/Pak-EPA on 10th of July, 2007 for the period of one month.     ii.            "Study Visit of Pakistani Government Officials on Crop Biotechnology" at Manila, Philippines (Aug 22-28, 2010).    iii.             Capacity Building on job training was offered to Pakistan by USDA and and Center for Environmental Risk Assessment (CERA) at Washington, USA. Two officers of National Biosafety Centre received this training in September, 2013.    These were one time activities and further capacity building and cooperation and colaborations are required for the effective implementation of the obligations of CPB under CBD. Therefore, further guidance and help is required form the CPB Secretrait  for securing bilaterial and multilateral cooperations.
Survey 9. Has your country adopted or used any guidance documents for the purpose of conducting risk assessment and/or risk management?
indicator 1.3.1.1
Survey 9.a) Risk assessment
  • Yes
Survey 9.b) Risk management
  • Yes
Here you may provide further details
The Guideance on Risk Assessment of Living Modified Organisms developed through the "Open-ended Online Forum" and the Ad Hoc Technical Expert Group (AHTEG) is used as guiding document for the risk assessment of LMOs and their Products.
Survey 10. Has your country adopted or used any guidance documents for the purpose of evaluating risk assessment reports submitted by notifiers?
indicator 1.3.1.2
  • Yes
Here you may provide further details
The Guideance on Risk Assessment of Living Modified Organisms developed through the "Open-ended Online Forum" and the Ad Hoc Technical Expert Group (AHTEG) is used as guiding document for the risk assessment of LMOs and their Products.
Survey 11. Has your country adopted any common approaches to risk assessment with other countries?
indicator 1.3.2
  • Yes
Here you may provide further details
The Guideance on Risk Assessment of Living Modified Organisms developed through the "Open-ended Online Forum" and the Ad Hoc Technical Expert Group (AHTEG) is used as guiding document for the risk assessment of LMOs and their Products. This guiding document provides common approcah for risk assessment of LMOs and their products
Survey 12. Has your country ever conducted a risk assessment of an LMO?
indicator 1.3.3
  • Yes
Here you may provide further details
Transgenic Cotton and Corn along with other GM crops had been in the research & development stages and evaluation for laboratory research & development and field testing is under process. Pakistan had commercialized eight Bt cotton varieities and one cotton hybrid. Risk assessment of LMOs and their Products is conducted as per the self developed guidelines based on the Guideance on Risk Assessment of Living Modified Organisms developed through the "Open-ended Online Forum" and the Ad Hoc Technical Expert Group (AHTEG).
Survey 13. Does your country have the capacity to identify, assess and/or monitor living modified organisms or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity, taking into account risks to human health?
indicator 1.4.2
Survey 13.a) Identify
  • Yes
Survey 13.b) Assess
  • Yes
Survey 13.c) Monitor
  • Yes
Here you may provide further details
Technical Advisory Committee under the guidance of National Biosafety Committee is involved in the above mentioned actvities. The Biotechnoloy laboratories had been desiganated for the identification of LMOs and their products and TAC Sub-committees had been involved in the process of moitor and assess the LMOs form Laoratory to field and after commercial release with respect to adverse effects to environment, biodiversity and human health. The Guideance on Risk Assessment of Living Modified Organisms developed through the "Open-ended Online Forum" and the Ad Hoc Technical Expert Group (AHTEG) is used as guiding document for risk assessment of LMOs and their products in the country.
Survey 14. Does your country have available any guidance for the purpose of ensuring the safe handling, transport, and packaging of living modified organisms?
indicator 1.6.4
  • Yes
Here you may provide further details
Pakistan is following the self developed guidelines for the purpose of ensuring the safe handling, transport, and packaging of LMOs and their products. These guidance are part of National Biosafety Guidelines 2005 for the above mentioned activities of LMOs and their products.
Survey 15. Does your country have any specific approaches or requirements that facilitate how socio-economic considerations should be taken into account in LMO decision making?
indicator 1.7.2
  • Yes
Here you may provide further details
The socio-economic considerations are part of the evaluation process and these consideration are taken into account for the decision making process for activities of LMOs and their products in the country.
Survey 16. How many peer-reviewed published materials has your country used for the purpose of elaborating or determining national actions with regard to socio-economic considerations?
indicator 1.7.1
  • One or more
Here you may provide further details
The published materials regarding socio-economic considerations are used for elaborating national actions during the evaluation process of the applications for activities related to LMOs and their products by Technical Advisory Committee and National Biosafety Committee also gives due weightage to it while considering the case for approval to carry out activities related to LMOs and their products in the country.     "BEST PRACTICES FOR ASSESSING THE SOCIAL AND ECONOMIC IMPACTS OF TRANSGENIC CROP VARIETIES ON SMALL-SCALE FARMERS" ,International Food Policy Research Institute, Washington, USA.     It is requested that any training material developed by the Secretariat or any country may be shared and if possible the trainings may be arranged for the decsion makers and the evaluators  for socio-economic considerations of CPB.
Survey 17. What is your country's experience, if any, in taking socio-economic considerations into account in LMO decision making?
indicator 1.7.3
The socio-economic considerations are given high priority while making decisions for the LMOs and their products related activities in the country. The socio-economic impacts are considered to be very important determinants for the biosafety clearance or otherwise specially for the commercial release of LMOs and their products. The possible socio-economic impacts of LMOs and their products related activities are throughly evaluated before reaching any decisionfor their release into environment even for the confined usage for testing. The confined field trials of GM cotton and corn are are approved considering socio-economic impacts on the farmers and society. some was true for the commercial release of Bt cotton in the country.  It is desired that trainings for inclusion of socio-economic considerations and evaluation of their impacts may be araanged for the evaluaors and decision makers along with share of any such materials.
Survey 18. Does your country have the capacity to take appropriate measures in the event that an LMO is unintentionally released?
indicator 1.8.3
  • No
Here you may provide further details
Pakistan has no capacity to take appropriate measures in the case of unintentional release of LMOS into the environment and  there is dire need to enhance the capacity and help in devising mechanisms and measures to control and regulate unintentional release of LMOs and their products in the country.
Survey 19. How many people in your country have been trained in risk assessment, monitoring, management and control of LMOs?
indicator 2.2.3
Survey 19.a) Risk assessment
  • 10 or more
Survey 19.b) Monitoring
  • 10 or more
Survey 19.c) Management / Control
  • 10 or more
Here you may provide further details
The specifically trained people are not available, the biotechnologist and moloecular biologists are conducting the risk assessment, monitoring and management/control and had been appraised about these activities like on job trainings.Specifically designed trainings and capacity building activities are required to further improve the process of risk assessment and risk management of LMOs and their products.
Survey 20. Does your country have the infrastructure (e.g. laboratory facilities) for monitoring or managing LMOs?
indicator 2.2.4
  • Yes
Here you may provide further details
There are biotechnolgy laboratories available which are being used for the indentification of LMOs by through gene and gene products. but no specific biosafety laboratoy is available and four biotechnology laboratories of different institutions had been desiganated to carry out identifaction and determination of concentration (Levels) of gene and gene products in different part of plants and other GM materials.  Therefor, financial and technical help is required for the establishment of a state of the art laboratory for conducting the monitoring or managing LMOs and that laboratory would also be a training facility for the other institutions and organizations involved in biotechnology and biosafety research and development activities.
Survey 21. Is your country using training material and/or technical guidance for training in risk assessment and risk management of LMOs?
indicator 2.2.5
  • No
Here you may provide further details
The Guideance on Risk Assessment of Living Modified Organisms developed through the "Open-ended Online Forum" and the Ad Hoc Technical Expert Group (AHTEG) is being  shared with the members of Technical Advisory Committee (TAC), Field Trials Monitoring  & Evaluation Committees and commercialization Committees for of GM Cotton and GM corn to evaluate its relevance and usage as guiding document for the risk assessment of LMOs and their Products. Therefore, finances and training materials are required for specific trainings of the members  of all the above mentioned committees for effective and efficient evaluation of the risk assessments and risk management of LMOs and their products.
Survey 22. Are the available training materials and technical guidance on risk assessment and risk management of LMOs sufficient and effective?
indicator 2.2.6
Survey 22.a) Sufficient
  • No
Survey 22.b) Effective
  • No
Here you may provide further details
The Guideance on Risk Assessment of Living Modified Organisms has been shared with the members of all the monitoring and evaluation committees but for effective and efficient risk assessment and risk managemnet the trainings are required. The financial and technical support is requested from the CPB Secretariat for the risk assessment of LMOs and their Products.
Survey 23. How many customs officers in your country have received training in the identification of LMOs?
indicator 2.3.1
  • None
Here you may provide further details
The customs officers had not been trained and they could only be trained to read and understand the information on the labels of the imported items of LMOs and/or the items containing LMOs producs. Therefore, it is requested that training materials developed by the CPB Secretariat or any other country be shared and funding may kindly be provided for the trainings of custom officers for the identification of LMOs and their products imported in the country or exported from Pakistan.
Survey 24. How many laboratory personnel in your country have received training in detection of LMOs?
indicator 2.3.1
  • None
Here you may provide further details
Some of the academic institutions may have conducted any such trainings for the laboratory personnels but that specific information is not available with the National Biosafety Centre. The specific training are required and CPB Secretariat is requested to provide funding and training materials for the training of the laboratory personnels for identification, detection of LMOs and their products.
Survey 25. Does your country have reliable access to laboratory facilities for the detection of LMOs?
indicator 2.3.2
  • Yes
Here you may provide further details
The four desiganated institutional biotechnolgy laboratories have adequate facilties and experties for the detection of the LMOs and their products. But, the reliability is question mark as these institutions are also the applicant for the research, developement and commercial release of GM producs in the country. Therefore, it is requested that financial and technical support may be provided for the establishment of National Biosafety Laboratories to address the reliability concern and also to provide training facilities to the organizatios and institutes in the field of detection and biosafety studies of LMOs and their products.
Survey 26. How many laboratories in your country are certified for LMO detection?
indicator 2.3.3
  • One or more
Here you may provide further details
There are no certified laboratories for the detection of LMOs and their products in the country. The National Biosafety Committee had desigated four institutional biotechnology laboratories to carryout identifaction, detection and determination of concentration (Level) of gene and gene products from different part of plants and other GM materials provided for qualitative and quantitative analysis.   It is required that a biosafety laboratories facility may kindly be funded and training provided to the personnel of the laboratories for the detection and determination of the LMOs and their products and also to train the other laboratories personnelsin the fields of identification and determination of LMOs and their products.
Survey 27. How many of the certified laboratories in the previous question are operational?
indicator 2.3.4
  • None
Here you may provide further details
No certified laboratory for the dection of LMOs and their products exists. Only the four designated institutional biotechnology laboratories for the qualitative and quantitative determination of gene and gene products are operational. There is a dire need for the National Biosafety Laboratories to be established for detections, determinations and trainings to labratories personnels to conduct the identification and quantification of LMOs and their products.
Survey 28. Has your country received any financial and/or technical assistance for capacity-building in the area of liability and redress relating to living modified organisms?
indicator 2.4.1
  • No
Here you may provide further details
N/A
Survey 29. Does your country have administrative or legal instrument that provide for response measures for damage to biodiversity resulting from living modified organisms?
indicator 2.4.2
  • Yes
Here you may provide further details
In the Pakistan Biosafety Rules 2005 and National Biosafety Guidelines 2005, the damage to the biodiversity are included but the decision makers, evaluators and monitors of LMOs and their products had not any specific training even to identify the possible/ potential damages to the biodiversity so administrative response measures for damage to biodiversity form LMOs and their products could not be developed. It is requesed that the capacity of the decision makers, evalucators and monitors may kindly be developed through providing training materials and fainances to conduct such trainings.
Survey 30. Has your country informed the public about existing modalities for public participation in the decision-making process regarding living modified organisms?
indicator 2.5.2
  • No
Here you may provide further details
National Biosafety Centre had organized a number of awareness activities for the general Public about the LMOs and their products. The following mass awareness of LMOs and their products measures were taken;  i. Public notices were released in the leading Newspapers of the country for information regarding Genetically Modified Organisms (GMOs) are subject to Pakistan Biosafety Rules, 2005.  ii. A brochure on "Biosafety & Genetically Modified Organisms" is prepared, approved by competent authority,published and widely distributed.  iii. An article "GMOs and Role of National Biosafety Centre" The Diplomatic Insight (2011) 4(6) page # 8  iv. Participate as "Environmental Expert" and delivered talks on Biosafety, LMOs and other environmental issues and their impacts in "Mahool Zaindgi Hai" and other programs on different channels of Radio of Pakistan.  v. Participated in a Rohi Television Channel programme to highlight "The GM crops (Bt cotton) and related Biosafety issues".  National Biosafety Centre is intrested to develop and publish handbills, brochures and hang ons and posters to educate and inform the public about LMOs and their products. But technical and financial constrians are not allowing to execute such activities. Therefore, it is requested kindly to provide technical and financial support to carry out such activities.  The civil society organizations are part of the decision making process and their involvment will be further increased.
Survey 31. If you answered yes to the previous question, please indicate the modalities used to inform the public?
indicator 2.5.2
  • National website
  • Newspaper
  • Forums
  • The invited lectures were delivered to different stakeholders and general public on biosafety of LMOs and their products.
Survey 32. If you indicated multiple modalities for public participation in the question above, which one was most used?
indicator 2.5.2
  • Forums
Here you may provide further details
The invited lectures were delivered to different stakeholders and general public on biosafety of LMOs and their products and other issues and concern of biosafety of LMOs and their products to the biodiversity and environment.
Survey 33. How many academic institutions in your country are offering biosafety education and training courses and programmes?
indicator 2.7.1
  • 5 or more
Here you may provide further details
The universities and other acdemic institutions of the country are offering biosafety related courses in their biotechnology degree curriculums. For example Quaid-i-Azam University, Islambad, PMAS Arid Agriculture University, Rawalpindi, University of Agriculture, Faisalabad, National Institute of Biology and Genetic Engineering, Faisalabad, COMSATS Institute of Information Technology, Islamabad etc.
Survey 34. How many biosafety training materials and/or online modules are available in your country?
indicator 2.7.2
  • None
Here you may provide further details
Pakistan had not developed any such biosafety training materials and/or online modules. Therefore, the help of the CPB Secretariat is required to develop biosafety training materials and modules and to made them online available.
Survey 35. Does your country have in place a monitoring and/or an enforcement system?
indicator 3.1.6
Survey 35.a) Monitoring system
  • Yes
Survey 35.b) Enforcement system
  • Yes
Here you may provide further details
Pakistan Biosafety Rules 2005 had been devised under Pakistan Environmental Protection Act 1997. The monitring system is devised in the Pakistan Biosafety Rules 2005 and the enforcement is under Pakistan Enviromental Prtection Act 1997. The evader of the Rules would be punshed as per provisions of the Act.   The monitoring and enforcement are not adequate and it is requested kindly to provide guidances and trainings for the effective implementation of monitroing and enforcement system in the country.
Survey 36. Please indicate the number of regional, national and international events organized in relation to biosafety (e.g. seminars, workshops, press conferences, educational events, etc.,) in the last 2 years.
indicator 4.3.1
  • 5 or more
Here you may provide further details
Six national workshop and seminars had been organized in the last two years for the information sharing, awareness and capacity building of the stakeholsders, students and general public in the country. No international activities could be executed due to lack of funds and cooperation form international donors/organizations. The details are as followes:  i. One day International Workshop, "Global Status, Impact and Future Prospects of Biotech Crops" organized by NBC in collaboration with M/s Monsanto Pakistan (Pvt.) Limited, Lahore on January 10, 2012.  ii. An Invited Lecture titled "Genetically Modified Products and their Regulation in Pakistan" Directorate of Health, Capital Development Authority (CDA), Islamabad on September 17, 2012.  iii. An Invited Lecture titled "Biosafety Laws and their Implementation" In the 121th Extra Ordinary General Body Meeting of Farmers Associates Pakistan (FAP), Lahore on November 13, 2012.  iv. An Invited Lecture titled "Responsibilities and Functions of Institutional Biosafety Committee under Pakistan Biosafety Rules 2005" at Faculty of Biological Sciences, Quad-i-Azam University, Islamabad on March 28, 2013.  v. "Capacity Building and Training Presentations on Trait Purity and GM Testing for TAC members and National Biosafety Centre officers" organized by NBC in collaboration with M/s Monsanto Pakistan (Pvt.) Limited, Lahore on April 10, 2013.  vi. "Hazardous Impacts of Pesticides in Environment and their Possible Alternatives" organized by TheNetwork for Consumer Protection at National University of Science and Technology, Islamabad on 10th October, 2013.
Survey 37. Please indicate the number of biosafety related publications that has been made available in your country in the last year.
indicator 4.3.2
  • None
Here you may provide further details
No biosafety related publication was made available in the country in the last year. The support is requested to develop and publish such materials and made available to the public and stakeholders on the biosafety related issues and concerns.
Survey 38. If biosafety related publications were made available (see question above), please indicate which modalities were preferred.
indicator 4.3.2
  • National web site and National Libraries
Survey 39. How many collaborative initiatives (including joint activities) on the Cartagena Protocol and other Conventions and processes has your government established in the last 4 years?
indicator 5.2.1
  • None
Here you may provide further details
N/A
Survey 40. Does your country have any awareness and outreach programmes on biosafety?
indicator 5.3.1
  • No
Here you may provide further details
N/A
Survey 41. If you answered yes to the question above, please indicate what entity is responsible for carrying out the programmes and/or services and at which level the programmes take place.
indicator 5.3.1
E.g. local, national, etc.,
N/A
Survey 42. Has your country designed and/or implemented an outreach/communication strategy on biosafety?
indicator 5.3.2
  • No
Here you may provide further details
N/A
Survey 43. Please indicate the number of educational materials on biosafety that are available and accessible to the public.
indicator 5.3.4
  • One or more